A randomized, double blind, placebo-controlled trial of rosiglitazone in young adults with uncomplicated malaria resulted in increased parasite clearance times and increased circulating levels of endothelial stabilizing and neuroprotective factors, including Ang-1 and brain-derived neurotrophic factor (BDNF), respectively [51]. Here, ANGPT1 is linked to malaria.